title: BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines.
authors.affiliation: Department of Pharmacology & Experimental Therapeutics, The Center for Cancer Research, Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, MA, USA.
authors.forename: N M
authors.initials: NM
authors.lastname: Anderson
authors.affiliation: Department of Pharmacology & Experimental Therapeutics, The Center for Cancer Research, Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, MA, USA.
authors.forename: I
authors.initials: I
authors.lastname: Harrold
authors.affiliation: 1] Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA, USA [2] Department of Haematology, University College London Cancer Institute, University College London, London, UK.
authors.forename: M R
authors.initials: MR
authors.lastname: Mansour
authors.affiliation: Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
authors.forename: T
authors.initials: T
authors.lastname: Sanda
authors.affiliation: Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
authors.forename: M
authors.initials: M
authors.lastname: McKeown
authors.affiliation: Department of Pharmacology & Experimental Therapeutics, The Center for Cancer Research, Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, MA, USA.
authors.forename: N
authors.initials: N
authors.lastname: Nagykary
authors.affiliation: Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
authors.forename: J E
authors.initials: JE
authors.lastname: Bradner
authors.affiliation: Department of Computer Science, Metropolitan College, Boston University, Boston, MA, USA.
authors.forename: G
authors.initials: G
authors.lastname: Lan Zhang
authors.affiliation: Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
authors.forename: A T
authors.initials: AT
authors.lastname: Look
authors.affiliation: Department of Pharmacology & Experimental Therapeutics, The Center for Cancer Research, Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, MA, USA.
authors.forename: H
authors.initials: H
authors.lastname: Feng
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D003561:Cytarabine / Q000494:pharmacology*; D004357:Drug Synergism; D006801:Humans; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D019253:Proto-Oncogene Proteins c-bcl-2; D013449:Sulfonamides; D003561:Cytarabine; C579720:venetoclax